Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients

Figures & data

Table 1 Characteristics of patients by treatment group (n, %)

Characteristic	Group Ia 73	Group IIb 92	P-value
ECOG performance status
0 or 1	60/73 (82.2%)	71/92 (77.2%)	0.429
>1	13/73 (17.8%)	21/92 (22.8%)
Sex
Male	43/73 (58.9%)	64/92 (69.6%)	0.154
Female	30/73 (41.1%)	28/92 (30.4%)
Stage
IIIA	35/73 (47.9%)	40/92 (43.5%)	0.567
IIIB	38/73 (52.1%)	52/92 (56.5%)
Histologic type
Squamous cell carcinoma	32/73 (43.8%)	21/92 (22.8%)	0.002
Adenocarcinoma	31/73 (42.5%)	64/92 (69.6%)
Other	10/73 (13.7%)	7/92 (7.6%)
Initial treatment
R	39/73 (53.4%)	45/92 (48.9%)	0.565
R+C	34/73 (46.6%)	47/92 (51.1%)
Smoking status
Smoker	38/73 (52.1%)	40/92 (43.5%)	0.273
Nonsmoker	35/73 (47.9%)	52/92 (56.5%)

Notes:

a Patients ≥70 years old, n=73.

b Patients <70 years old, n=92.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; R, radiotherapy; R+C, radiotherapy and chemotherapy.

Figure 1 Survival analysis in locally advanced lung cancer, stratified by groups I and II (P>0.05).

Table 2 Survival rates stratified by patient group (n, %)

	Group Ia	Group IIb	P-value
1-year survival	36/73 (49.3%)	37/92 (40.2%)	0.243
2-year survival	15/73 (20.5%)	15/92 (16.3%)	0.483
3-year survival	7/73 (9.6%)	9/92 (9.8%)	0.967

Notes:

a Patients ≥70 years old, n=73.

b Patients <70 years old, n=92.

Table 3 Toxicities stratified by patient group

	Group Ia	Group IIb	P-value
Anemia	4/73 (5.5%)	4/92 (4.3%)	0.737
Neutropenia	20/73 (27.4%)	27/92 (29.3%)	0.783
Thrombocytopenia	5/73 (6.8%)	7/92 (7.6%)	0.852
Esophagitis	24/73 (32.9%)	27/92 (29.3%)	0.626
Pneumonitis	13/73 (17.8%)	13/92 (14.1%)	0.520

Notes:

a Patients ≥70 years old, n=73.

b Patients <70 years old, n=92.